To offer the best possible experience tailored to your national regulatory requirements and the available product portfolio, please choose your country from the following list. This option will be saved throughout the browser session. Thank you!
19/06/2018

Eckert & Ziegler is Manufacturing Partner for Bayer’s Innovative Targeted Thorium Conjugates in Europe

Berlin, Germany

Eckert & Ziegler AG, a specialist for scientific, medical, and industrial applications of radioisotopes, has been selected as manufacturing partner for clinical supply of Bayer’s innovative Targeted Thorium Conjugates (TTCs) in Europe. TTCs are a versatile, next-generation targeted alpha therapy (TAT). The approach uses tumor targeting molecules such as antibodies that carry alpha-particle emitting Thorium-227 to the tumor. TTCs have the potential to be used in a broad range of tumors, and also for patients who are refractory to chemotherapy or conventional targeted oncologics. Bayer has established scalable Good Manufacturing Practices (GMP) processes for the alpha-emitter Thorium-227. Eckert & Ziegler will provide the infrastructure for handling, manufacture and distribution of the TTCs for the purpose of clinical trial testing in Europe.

‎”We are delighted to have been selected as a partner for this interesting and important product platform,” says Dr. André Heß, Member of the Executive Board of Eckert & Ziegler and Head of the Radiopharma Segment. “The decision demonstrates how well our Radiopharma Segment can support the requirements of innovative partners by the provision of exceptional radiopharmaceutical expertise, all of which is backed-up by a world-wide logistics infrastructure. We are excited about the potential of this innovative platform technology as Thorium-227 can be coupled with various biomolecules addressing different tumor types.”

About Eckert & Ziegler
Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700) is one of the world’s largest providers of isotope technology for radiation therapy and nuclear medicine and has around 800 employees worldwide. It globally provides nuclear medicine institutions with synthesis technology, quality control instruments, and pharmaceutical grade radioisotopes, among them Yttriga, a precursor for Yttrium based oncology products, and GalliaPharm®, a Gallium-68 radionuclide generator for diagnostic applications.
Contributing to saving lives.

Contact:
Eckert & Ziegler AG
Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.dewww.ezag.com

Note: The press release has been copied from www.ezag.com

Contact

Get in touch

Contact us regarding your questions and we will get back to you as soon as possible.
By clicking send, you give your consent for processing your personal data in accordance with our Data Privacy Statement.